title: [Companion Diagnostics for Selecting Antiretroviral Drugs against HIV-1].
abstract: Currently, the treatment of human immunodeficiency virus involves combination therapy, as antiretroviral therapy(ART). The treatment has improved steadily since the advent of potent combination therapy in 1996. New drugs that offer new mechanisms of action, improvements in potency and activity even against multidrug-resistant viruses, dosing convenience, and tolerability have been approved. Among ART with useful drugs, there are two important examinations before starting the treatment using the two kinds of drug. CCR5 co-receptor antagonists, maraviroc, prevent HIV entry into target cells by binding to CCR5 receptors. Genotypic assays have been developed that can determine or predict the co-receptor tropism(i.e., CCR5, CXCR4, or both) of the patient's dominant virus population. The assay for HIV-1 co-receptor usage should be performed whenever the use of a CCR5 antagonist is being considered. One of the nucleoside/nucleotide reverse transcriptase inhibitors (NRTIs), abacavir, is an important agent to develop recommended regimens for antiretroviral therapy. Serious and sometimes fatal hypersensitivity reactions have been associated with abacavir-containing products, ZIAGEN, Epzicom, and Triumeq. Patients who carry the HLA-B*5701 allele are at high-risk of a hypersensitivity reaction to abacavir. Prior to initiating therapy with abacavir, performing a screening test for the HLA-B*5701 allele is recommended. [Review].
authors.forename: Katsuyuki
authors.initials: K
authors.lastname: Fukutake
mesh_terms: D000483:Alleles; D044966:Anti-Retroviral Agents / Q000008:administration & dosage* / Q000494:pharmacology; D065100:CCR5 Receptor Antagonists; D003510:Cyclohexanes / Q000008:administration & dosage / Q000494:pharmacology; D015224:Dideoxynucleosides / Q000008:administration & dosage / Q000494:pharmacology; D015658:HIV Infections / Q000175:diagnosis* / Q000188:drug therapy* / Q000235:genetics / Q000821:virology; D015497:HIV-1 / Q000502:physiology; D015235:HLA-B Antigens / Q000235:genetics; D006801:Humans; D000077592:Maraviroc; D010597:Pharmacogenetics; D057285:Precision Medicine; D018894:Reverse Transcriptase Inhibitors; D014230:Triazoles / Q000008:administration & dosage / Q000494:pharmacology; D056189:Viral Tropism / Q000187:drug effects; D000099227:Abacavir
chemical_list: D044966:Anti-Retroviral Agents; D065100:CCR5 Receptor Antagonists; D003510:Cyclohexanes; D015224:Dideoxynucleosides; D015235:HLA-B Antigens; D000077592:Maraviroc; D018894:Reverse Transcriptase Inhibitors; D014230:Triazoles; D000099227:Abacavir